10-K/A: Greenland Mines Ltd Amends 2025 10-K Filing

Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) filed an amendment to its 2025 10-K, revising disclosures related to its business, financial results, and financial statements following SEC comments.

Summary

• Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) has filed an Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025.
• This amendment addresses comments received from the SEC's Division of Corporation Finance.
• Key revisions include updated disclosures in Item 1 (Business) regarding product candidate timelines, licensing agreements, and in Item 7 (Management's Discussion and Analysis) concerning professional fees, general and administrative expenses, and research and development expenses.
• Item 8 (Financial Statements) also sees revisions to the Consolidated Statements of Operations, Changes in Stockholders Equity, and notes related to intangible assets and warrants.
• The company is developing medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders, with a focus on gene therapy for neurodegenerative diseases and biosimilar biologics.
• A significant development was the acquisition of Greenland Mines Corp. in March 2026, expanding operations into mineral development and mining.
• The company reported a net loss of $10,551,674 for the year ended December 31, 2025, an increase from the prior year's net loss of $6,150,372.
• As of December 31, 2025, the company had $7,176,615 in cash and cash equivalents and a working capital of $7,216,922, but faces substantial doubt about its ability to continue as a going concern without additional funding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to the company's ongoing financial losses, substantial cash burn, and the significant risks associated with its early-stage drug development pipeline, despite recent financing activities and a strategic acquisition.

Positives

• The company has secured licenses for key technologies in gene therapy and biosimilars.
• A significant strategic acquisition of Greenland Mines Corp. in March 2026 diversified the company's operations into mineral development.
• The company has actively pursued financing, raising approximately $13.0 million in net cash from financing activities for the year ended December 31, 2025.
• The company has a Scientific Advisory Board with notable experts in neurodegenerative diseases and longevity.
• The company has entered into various license and sponsored research agreements to advance its product pipeline.

Negatives

• The company incurred a net loss of $10,551,674 for the year ended December 31, 2025, and has a history of significant losses.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• Operating expenses increased significantly in 2025, driven by professional fees, general and administrative costs, and R&D expenses.
• The company's product candidates are in early stages of development (pre-clinical or clinical) and may never achieve regulatory approval or commercial success.
• The company faces intense competition in the biosimilar market and from other gene therapy developers.
• The company received a delinquency notification from Nasdaq regarding its minimum bid price and faces potential delisting if compliance is not achieved by September 14, 2026.

Risks

• The company has incurred significant losses and expects to continue incurring losses, with no guarantee of achieving profitability.
• Substantial additional funding is required to meet financial obligations and pursue business objectives.
• Reliance on collaborations, particularly with UAB, for preclinical research and development.
• Negative public opinion or increased regulatory scrutiny of gene therapy could adversely impact product development and commercial success.
• The company is dependent on the success of its early-stage biosimilar and gene therapy product candidates, with no products currently approved for commercial sale.
• Failure to obtain necessary financing could prevent the company from completing development and commercialization of its product candidates.
• The company is highly dependent on its key executives and personnel, and the loss of such individuals could harm the business.
• The company faces risks related to intellectual property, including potential infringement claims and the ability to protect its own IP.

Future Outlook

The company expects to continue incurring significant operating losses and negative cash flows from operations. Its ability to continue operations and execute its development plans is dependent on obtaining additional working capital funding through the sale of equity and/or debt securities. The company has not generated revenue and does not expect to until its gene therapy product candidates are successfully developed and approved.

Management Comments

• Management believes that professional fees in future periods may moderate relative to 2025 levels as certain transaction-related activities are completed.
• Management expects general and administrative expenses to increase in 2026 as compared to 2025 primarily due to an increase in operational activity, public company and corporate communications expenses, and non-cash stock-based compensation.
• Management expects research and development expenses to continue to represent a significant component of operating expenses as product candidates advance.
• Management believes that a portion of the increase in cash used in operating activities during 2025 reflects temporary expansion-related costs, while continued operating expenses are expected to remain elevated relative to prior periods as a result of operating as a public company.

Industry Context

StockSavvy.ai notes that Greenland Mines Ltd operates in the highly competitive and capital-intensive biotechnology sector, focusing on gene therapy and biosimilars. The company's strategy involves in-licensing technology and advancing product candidates through pre-clinical and clinical development, a path fraught with high failure rates and significant funding requirements. The recent diversification into mining through the Greenland Mines Corp. acquisition represents a significant strategic shift, potentially altering the company's risk profile and operational focus.

Comparison to Industry Standards

• The company's net loss of $10.55 million for the year ended December 31, 2025, and its accumulated deficit of $21.1 million, are substantial for a pre-revenue biotechnology company, indicating a high cash burn rate typical of the sector but requiring continuous access to capital.
• The company's reliance on external financing for operations is standard in the biotech industry, where R&D costs are high and product commercialization is years away.
• The company's focus on gene therapy for neurodegenerative diseases like Alzheimer's and ALS aligns with a growing area of research, but also faces significant scientific and regulatory hurdles, similar to other companies in this space.
• The company's struggle to maintain a minimum bid price on Nasdaq is a common challenge for small-cap biotech firms that have not yet achieved commercial success or significant clinical milestones.

Legal Proceedings

• None are explicitly detailed in this section of the filing.

Related Party Transactions

• Notes payable to related parties were outstanding as of December 31, 2024, but were paid off by December 31, 2025.
• Employment agreements are in place with key executives, including Dr. Joseph Sinkule (CEO) and Jeffrey LeBlanc (CFO), with associated salaries and equity awards.

Stakeholder Impact

• Shareholders may experience dilution if the company issues more equity to raise capital.
• The company's ability to continue as a going concern poses a risk to all stakeholders.
• Potential delisting from Nasdaq could negatively impact share liquidity and investor confidence.
• The success or failure of the company's drug development programs will directly impact the value of shareholder investments.

Next Steps

• The company plans to start the first-in-human Phase I/II Compassionate Use study of KLTO-202 in late-stage ALS patients in 2027.
• The pre-clinical development program for KLTO-101 is expected to follow KLTO-202 by six to nine months.
• The company plans to find a corporate partner to help in the development of KLTO-101.
• The company will continue to build integrated internal development capabilities from product development through commercialization.
• The company will continue to explore potential opportunities to acquire or license new product candidates and for partnership or collaboration on existing products.
• The company must regain compliance with Nasdaq's minimum bid price rule by September 14, 2026, to avoid delisting.

Key Dates

Recommendation

The company is in a highly speculative, early-stage development phase with significant financial risks and a history of losses. While the acquisition of Greenland Mines Corp. offers diversification, the core biotech business remains high-risk. The company's ability to secure further funding and achieve clinical milestones is critical. Given the uncertainties and the need for more de-risked progress, a 'hold' recommendation is appropriate, advising investors to monitor future developments closely.

Keywords

gene therapy, Alzheimer's disease, ALS, Klotho protein, biosimilar, drug development, clinical trials, SEC filing